Slingerland, M., & Gelderblom, H. (2011). The fate of camptothecin glycoconjugate: Report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan. Springer US.
Chicago Style aipamenaSlingerland, Marije, and Hans Gelderblom. The Fate of Camptothecin Glycoconjugate: Report of a Clinical Hold During a Phase II Study of BAY 56-3722 (formerly BAY 38-3441), in Patients With Recurrent or Metastatic Colorectal Cancer Resistant/refractory to Irinotecan. Springer US, 2011.
MLA aipamenaSlingerland, Marije, and Hans Gelderblom. The Fate of Camptothecin Glycoconjugate: Report of a Clinical Hold During a Phase II Study of BAY 56-3722 (formerly BAY 38-3441), in Patients With Recurrent or Metastatic Colorectal Cancer Resistant/refractory to Irinotecan. Springer US, 2011.